Rhythm Pharmaceuticals (RYTM) closed at $110.68 on November 4, 2026, up 28.0% from the previous close, on volume of 3,783,787 shares (30-day average 928,780).
Data as of November 4, 2026.
Rhythm Pharmaceuticals jumps on report AstraZeneca made $10B bid
Seeking Alpha News (Wed, 4-Nov 4:13 PM ET)
RYTM Rallies After NICE Expands IMCIVREE Reimbursement to Adults With Bardet-Biedl Syndrome
Market Chameleon (Wed, 4-Nov 6:17 AM ET)
TipRanks (Wed, 4-Nov 8:30 AM ET)
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
TipRanks (Wed, 4-Nov 5:16 AM ET)
Market Chameleon (Tue, 3-Nov 2:40 AM ET)
Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5M
Seeking Alpha News (Tue, 3-Nov 7:18 AM ET)
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Globe Newswire (Mon, 2-Nov 9:59 PM ET)
Rhythm Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 2-Nov 11:11 AM ET)
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals trades on the NASDAQ stock market under the symbol RYTM.
As of November 4, 2026, RYTM stock price climbed to $110.68 with 3,783,787 million shares trading.
RYTM has a beta of 1.58, meaning it tends to be more sensitive to market movements. RYTM has a correlation of 0.19 to the broad based SPY ETF.
RYTM has a market cap of $7.62 billion. This is considered a Mid Cap stock.
Last quarter Rhythm Pharmaceuticals reported $92 million in Revenue and -$.61 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.12.
In the last 3 years, RYTM traded as high as $122.20 and as low as $23.83.
The top ETF exchange traded funds that RYTM belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.
RYTM has underperformed the market in the last year with a return of -2.7%, while SPY returned +13.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RYTM shares. However, RYTM has outperformed the market in the last 3 month and 2 week periods, returning +7.7% and +22.7%, while SPY returned +1.5% and -0.3%, respectively. This indicates RYTM has been having a stronger performance recently.
RYTM support price is $84.34 and resistance is $88.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RYTM shares will trade within this expected range on the day.